University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor technologies. [Penn Medicine] Press Release Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases Synthetic Biologics, Inc. and Intrexon Corporation entered into a second worldwide exclusive channel collaboration through which Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies. [Synthetic Biologics, Inc.] Press Release Northwest Bio Expands Worldwide Production Capacity for DCVax®-L Northwest Biotherapeutics announced that it is entering into amended agreements to double the production capacity in the U.S. for the manufacture of the Company’s DCVax®-L immune therapy for Glioblastoma multiforme patients. [Northwest Biotherapeutics] Press Release |